Home Newsfeeds SES AI Q3 EPS $(0.08), Inline

SES AI Q3 EPS $(0.08), Inline

SES AI (NYSE:SES) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate.

byBenzinga Newsdesk

November 9, 2022

1 minute read

SES AI (NYSE:SES) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate.

Red Light Holland’s Q1 2024 Performance: Revenue Soars 53% And Solid Cash Balance

By Lara Goldstein

August 29, 3:28 PM

Ontario-based mushrooms producer Red Light Holland Corp. (OTCQB: TRUFF) filed its quarterly financial statements, management discussion and analysis for the three months ended June 30. The Numbers:

TRUFF

Deutsche Bank Maintains Hold on PACCAR, Lowers Price Target to $94

By Benzinga Newsdesk

July 13, 8:37 AM

Deutsche Bank analyst Nicole Deblase maintains PACCAR (NASDAQ:PCAR) with a Hold and lowers the price target from $97 to $94.

PCAR

Micron Ordered To Pay $445M Penalty For Patent Violation: Report

By Shivani Kumaresan

May 24, 6:23 AM

Micron Technology has been reportedly ordered to pay $445 million to Netlist for patent infringement on high-performance memory-module technology. The jury in the U.S. District Court for the Eastern District of Texas found Micron's actions to be willful.

FEPI

Inozyme Outlines Plans For Pediatric Trial For ENPP1 Deficiency Treatment: Targets 2026 Commercial Launch For INZ-701

By Vandana Singh

July 26, 2:45 PM

Following meetings with the FDA and the European Medicines Agency's Paediatric Committee, Inozyme Pharma Inc (NASDAQ: INZY) updated its global development strategy for INZ-701, a

INZY

SES AI Q3 EPS $(0.08), Inline

Related Posts

Red Light Holland’s Q1 2024 Performance: Revenue Soars 53% And Solid Cash Balance

Deutsche Bank Maintains Hold on PACCAR, Lowers Price Target to $94

Micron Ordered To Pay $445M Penalty For Patent Violation: Report

Inozyme Outlines Plans For Pediatric Trial For ENPP1 Deficiency Treatment: Targets 2026 Commercial Launch For INZ-701